Abstract:Therapeutic administration of recombinant proteins has been used for the treatment of various diseases in multiple studies. Herein, we investigated the function of the acute phase protein Orosomucoid 2 (Orm2), which is mainly secreted by hepatocytes, and evaluated its potential as a therapeutic strategy for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). We here revealed that a high expression of Orm2 protected mice from high-fat diet (HFD)-induced obesity. The pharmacological administration of recombinant ORM2 protein attenuated hepatic steatosis, inflammation, hepatocyte injury, and fibrosis in mouse livers, which suffered NAFLD and NASH under dietary challenge conditions. Orm2 knockout mice spontaneously underwent obese after 16 weeks under normal diet. Orm2 deficiency exacerbated HFD-induced steatosis, steatohepatitis, and fibrosis in mice. Mechanistically, the deletion of Orm2 led to the activation of the Erk1/2-PPARγ-Cd36 signaling pathway, which in turn increased fatty acid uptake and absorption in hepatocytes and mice. Collectively, our results provide Orm2 is an essential factor for preventing NASH and associated NAFLD under obesity. ### Competing Interest Statement The authors have declared no competing interest. * Acsl1 : acyl-CoA synthetase long chain family member 1 ALT : alanine aminotransferase Ap2 : integrase-type DNA-binding superfamily protein AST : aspartate aminotransferase Atgl : Adipose triglyceride lipase BAT : brown adipose tissue BCA : bicinchoninic acid Cpt1ɑ : carnitine palmitoyltransferase 1A Cxcl10 : C-X-C motif chemokine ligand 10 Dgat : diacylglycerol O-acyltransferase ECL : enhanced chemiluminescence Erk1/2 : mitogen-activated protein kinase eWAT : epididymal white adipose tissue Fasn : Fatty Acid Synthase FFA : free fatty acid FGF : fibroblast growth factor HDL : high-density lipoprotein H&E : hematoxylin and eosin HFD : high fat diet IL1β : interleukin 1 beta IP-ITT : intraperitoneal insulin-tolerance tests IPTG : isopropyl-β-D-1-thiogalactopyranoside ITPR2 : inositol 1,4,5-trisphosphate receptor type 2 KO : Orm2 knockout mice LDL : low-density lipoprotein MCD : methionine and choline-deficient L-amino acid diet Mcp1 : Monocyte chemoattractant protein-1 NAFLD : non-alcoholic fatty liver disease NASH : non-alcoholic steatohepatitis NCBI : national center for biotechnology information OA : oleic acid O-GTT : oral glucose tolerance Orm2 : Orosomucoid 2 PA : palmitic acid PMSF : phenylmethanesulfonylfluoride or phenylmethylsulfonyl fluorid PPAR : peroxisome proliferator activated receptor RT-qPCR : real time quantitative PCR SHBG : sex hormone-binding globulin SMA : smooth muscle STAT1 : Signal Transducer And Activator Of Transcription TBST : Tris buffered saline with Tween-20 TC : total cholesterol TG : triglyceride T2DM : type 2 diabetes mellitus WT : wild type mice

Restoring Ornithine Transcarbamylase (OTC) Activity in an OTC‐deficient Mouse Model Using LUNAR‐OTC Mrna

Expression of Ornithine Transcarbamylase Deficiency in the Small Intestine and Colon of Sparse‐Fur Mutant Mice

Corticosteroid suppresses urea-cycle-related gene expressions in ornithine transcarbamylase deficiency

Design, Synthesis, and Mechanistic Studies of ( R )-3-Amino-5,5-difluorocyclohex-1-ene-1-carboxylic Acid as an Inactivator of Human Ornithine Aminotransferase

A Novel Mutation In Ornithine Transcarbamylase Gene Identified From A Chinese Child With Ornithine Transcarbamylase Deficiency

Analysis of Urinary Markers for Ornithine Transcarbamylase Deficiency by Gas Chromatography-Mass Spectrometry

Recapitulation of Skewed X-Inactivation in Female Ornithine Transcarbamylase-Deficient Primary Human Hepatocytes in the FRG Mouse: A Novel System for Developing Epigenetic Therapies

Biochemical Studies on Human Ornithine Aminotransferase Support a Cell-Based Enzyme Replacement Therapy in the Gyrate Atrophy of the Choroid and Retina

Impact of citrulline substitution on clinical outcome after liver transplantation in carbamoyl phosphate synthetase 1 and ornithine transcarbamylase deficiency

Hematopoietic Stem Cell-Targeted Neonatal Gene Therapy with a Clinically Applicable Lentiviral Vector Corrects Osteopetrosis in oc/oc Mice

Cell-Free Synthesis Of Ornithine Decarboxylase - Changes In Messenger-Rna Activity In The Liver Of Thioacetamide-Treated Rats

Benefits of tailored disease management in improving tremor, white matter hyperintensities, and liver enzymes in a child with heterozygous X-linked ornithine transcarbamylase deficiency

Retrospective evaluation of serum ornithine carbamyltransferase activity as an index of hepatotoxicity in toxicological studies with rats

Treatment of non-alcoholic steatohepatitis with recombinant Orosomucoid 2, an acute phase protein that attenuates the Erk1/2-PPARγ-Cd36 signaling pathway

Combinatorial Approach of Lc-Ms/Ms and Lc-Tof-Ms for Uncovering in Vivo Kinetics and Biotransformation of Ochratoxin A in Rat

Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the novel NAMPT Inhibitor OT-82

Human organic anion transporting polypeptide (OATP) 1B3 and mouse OATP1A/1B affect liver accumulation of Ochratoxin A in mice

Ornithine Aminotransferase Promoted The Proliferation And Metastasis Of Non-Small Cell Lung Cancer Via Upregulation Of Mir-21

Characterization of Organic Anion-Transporting Polypeptide (oatp) 1a1 and 1a4 Null Mice Reveals Altered Transport Function and Urinary Metabolomic Profiles.

3.3 IN VIVO KINETICS AND METABOLIC STUDY OF OCHRATOXIN A IN RAT

[Expression and Bioinformatic Analysis of Ornithine Aminotransferase in Non-Small Cell Lung Cancer].